| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10017892 | HBV | ENSG00000000971.17 | protein_coding | CFH | No | No | 3075 | A0A0D9SG88 P08603 |
| TVIS10019263 | HBV | ENSG00000000971.17 | protein_coding | CFH | No | No | 3075 | A0A0D9SG88 P08603 |
| TVIS10008670 | HBV | ENSG00000000971.17 | protein_coding | CFH | No | No | 3075 | A0A0D9SG88 P08603 |
| TVIS10018396 | HBV | ENSG00000000971.17 | protein_coding | CFH | No | No | 3075 | A0A0D9SG88 P08603 |
| TVIS10004618 | HBV | ENSG00000000971.17 | protein_coding | CFH | No | No | 3075 | A0A0D9SG88 P08603 |
| TVIS10025184 | HBV | ENSG00000000971.17 | protein_coding | CFH | No | No | 3075 | A0A0D9SG88 P08603 |
| TVIS10026044 | HBV | ENSG00000000971.17 | protein_coding | CFH | No | No | 3075 | A0A0D9SG88 P08603 |
| TVIS10026045 | HBV | ENSG00000000971.17 | protein_coding | CFH | No | No | 3075 | A0A0D9SG88 P08603 |
| TVIS10050350 | HBV | ENSG00000000971.17 | protein_coding | CFH | No | No | 3075 | A0A0D9SG88 P08603 |
| TVIS10060139 | HBV | ENSG00000000971.17 | protein_coding | CFH | No | No | 3075 | A0A0D9SG88 P08603 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CFH |
|---|---|
| DrugBank ID | DB01593 |
| Drug Name | Zinc |
| Target ID | BE0009053 |
| UniProt ID | P08603 |
| Regulation Type | |
| PubMed IDs | 21396937 |
| Citations | Nan R, Farabella I, Schumacher FF, Miller A, Gor J, Martin AC, Jones DT, Lengyel I, Perkins SJ: Zinc binding to the Tyr402 and His402 allotypes of complement factor H: possible implications for age-related macular degeneration. J Mol Biol. 2011 May 13;408(4):714-35. doi: 10.1016/j.jmb.2011.03.006. Epub 2011 Mar 17. |
| Groups | Approved; Investigational |
| Direct Classification | Homogeneous transition metal compounds |
| SMILES | [Zn] |
| Pathways | Dihydropyrimidinase Deficiency; Rofecoxib Action Pathway; Losartan Action Pathway; AICA-Ribosiduria; Canavan Disease; Quinapril Action Pathway; Alkaptonuria; Eprosartan Action Pathway; gamma-Glutamyltransferase Deficiency; Pterine Biosynthesis; Sulindac Action Pathway; Rescinnamine Action Pathway; Piroxicam Action Pathway; Nabumetone Action Pathway; 2-Hydroxyglutric Aciduria (D and L Form); beta-Ureidopropionase Deficiency; Vitamin B6 Metabolism; Retinol Metabolism; Valsartan Action Pathway; Valdecoxib Action Pathway; Irbesartan Action Pathway; Adenosine Deaminase Deficiency; Hawkinsinuria; Methionine Metabolism; Ramipril Action Pathway; Benazepril Action Pathway; beta-Alanine Metabolism; Aspartate Metabolism; Diclofenac Action Pathway; Galactosemia |
| PharmGKB | PA451956 |
| ChEMBL | CHEMBL1201279 |
